key: cord-0975684-sie7dno4 authors: Zhao, Xiang-Na; You, Yue; Wang, Guo-Lin; Gao, Hui-Xia; Cui, Xiao-Ming; Duan, Li-Jun; Zhang, Sheng-Bo; Wang, Yu-Ling; Lin-Yao,; Li, Li; Lu, Jian-Hua; Wang, Hai-Bin; Fan, Jing-Fang; Zheng, Huan-Wei; Dai, Er-Hei; Tian, Lu-Yi; Ma, Mai-Juan title: Longitudinal single-cell immune profiling revealed distinct innate immune response in asymptomatic COVID-19 patients date: 2020-09-03 journal: bioRxiv DOI: 10.1101/2020.09.02.276865 sha: e7847cb17f3dfe6fd5fe9b790494ec970559417c doc_id: 975684 cord_uid: sie7dno4 Recent studies have characterized the single-cell immune landscape of host immune response of coronavirus disease 2019 (COVID-19), specifically focus on the severe condition. However, the immune response in mild or even asymptomatic patients remains unclear. Here, we performed longitudinal single-cell transcriptome sequencing and T cell/B cell receptor sequencing on 3 healthy donors and 10 COVID-19 patients with asymptomatic, moderate, and severe conditions. We found asymptomatic patients displayed distinct innate immune responses, including increased CD56briCD16− NK subset, which was nearly missing in severe condition and enrichment of a new Th2-like cell type/state expressing a ciliated cell marker. Unlike that in moderate condition, asymptomatic patients lacked clonal expansion of effector CD8+ T cells but had a robust effector CD4+ T cell clonal expansion, coincide with previously detected SARS-CoV-2-reactive CD4+ T cells in unexposed individuals. Moreover, NK and effector T cells in asymptomatic patients have upregulated cytokine related genes, such as IFNG and XCL2. Our data suggest early innate immune response and type I immunity may contribute to the asymptomatic phenotype in COVID-19 disease, which could in turn deepen our understanding of severe COVID-19 and guide early prediction and therapeutics. Single-cell transcriptomes profiling of PBMCs from COVID-19 patients 87 In order to explore the immunological changes of patients with COVID-19, the 88 immune profiles of PBMCs from ten patients and three healthy donors (HD) were 89 analyzed by scRNA-seq with T cell and B cell receptor (TCR/BCR) sequencing using 90 the 10x Chromium platform (Figure 1a) . The demographics and clinical features of 91 these patients are shown in Table S1 . The ten patients were classified into severe 92 (Ps, n=1), moderate (Pm, n=7), and asymptomatic (Pa, n=2), aged 17 to 62 years 93 old, and 6 of them were male. A total of 31 blood samples were collected from 10 94 patients, and 8 of 10 patients provided blood samples ≥ three times at different time 129 To further characterize the T/NK subsets in detail, we extracted the data from T/NK 130 cells and repeated the data integration and clustering. With the refined clustering 131 analysis, we identified 14 cell subtypes (Figure 3a, b) , including rare clusters absent 132 in previous clustering analysis (Figure 1c; Figure S3a ). We identified four CD4 + T To gain insights into features in T/NK cell subtypes, we assessed the abundance 144 of each cell type across disease conditions and stages (Figure 3c; Figure S4b ). 145 Notably, the proportion of CD4 + TE significantly increased in asymptomatic patients Next, we sought to identify the specific signature of the NK and Th2-like innate 160 immune cells with distinct distribution in asymptomatic and severe conditions. We 223 We extracted single-cell B cells sequencing data and repeated the data integration proportion was observed over time for the samples of moderate patients (Figure 5c) . 230 Next, we analyzed the single-cell BCR sequencing data and reconstructed high-231 quality BCR sequences in more than 80% of the B cells. We found an apparent BCR (Figure 5g) . However, severe patients have much 262 higher expression of these genes (Figure 5g) , indicating more robust activation of 263 IFN-I signaling pathway response and a pro-inflammatory state. Notably, we also 264 found increased expression of STAT1 in severe patients (Figure 5g) , which was 265 consistent with a previous study (Zhu et al., 2020) . Despite the difference in adaptive immune response, there were profound 318 differences in innate immune responses between asymptomatic condition and others. Asymptomatic patients had significantly increased fractions of CD56 bri CD16 -NK cells 320 and their precursor (iNK), while the severe patient had increased CD56 dim CD16 + NK 321 subsets. Moderate patients had fewer CD56 bri CD16 -NK cells at the early stage, and 322 the fraction was increased at the later stage. We found CD56 bri CD16 -NK subsets 323 had upregulated cytokine-related genes such as XCL1, XCL2, and IFNG, consistent 324 with current knowledge that these regulatory cells act as potent cytokine and 325 chemokine producers. CD56 dim CD16 + NK cells are considered to be differentiated 326 from CD56 bri CD16 -NK cells and have more cytotoxic potential (Abel et al., 2018) . In The disease severity was defined as asymptomatic, moderate, and severe, Natural Killer Cells Improved scoring of functional 535 groups from gene expression data by decorrelating GO graph structure Reference-based analysis of lung single-cell 539 sequencing reveals a transitional profibrotic macrophage Clinical and immunological features of severe and 542 moderate coronavirus disease 2019 Epidemiological and clinical characteristics of 99 cases of 546 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study On the discovery of subpopulation-specific 550 state transitions from multi-sample multi-condition single-cell RNA sequencing data High number of CD56(bright) NK-554 cells and persistently low CD4+ T-cells in a hemophiliac HIV/HCV co-infected patient 555 without opportunistic infections Asymptomatic Transmission, the 557 Heel of Current Strategies to Control Covid-19 Complex Immune Dysregulation in COVID-19 Patients with Severe 562 Respiratory Failure Cutting Edge: Regulator 565 of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and 570 Change-O: a toolkit for analyzing large-scale B cell 573 immunoglobulin repertoire sequencing data Batch effects in 575 single-cell RNA-sequencing data are corrected by matching mutual nearest 576 neighbors Souporcell: robust clustering of single-cell RNA-579 seq data by genotype without reference genotypes FateID infers cell fate bias in multipotent 581 progenitors from single-cell RNA-seq data Clinical features of patients infected with 2019 novel coronavirus in 584 COVID-19 cytokine storm: the interplay between 586 inflammation and coagulation. The Lancet Respiratory medicine TROY, a newly identified member of the tumor necrosis factor 589 receptor superfamily, exhibits a homology with Edar and is expressed in embryonic 590 skin and hair follicles Structural cells are key regulators of organ-specific immune responses Human Tissue-Resident Memory T Cells 597 Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and 598 Immunophenotyping of COVID-19 and influenza 601 highlights the role of type I interferons in development of severe COVID-19 Single-cell landscape of bronchoalveolar immune cells in 605 patients with COVID-19 Clinical and immunological assessment of 608 asymptomatic SARS-CoV-2 infections Longitudinal analyses reveal 611 immunological misfiring in severe COVID-19 Deep 614 immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic 615 implications Scater: pre-617 processing, quality control, normalization and visualization of single-cell RNA-seq 618 data in R COVID-19: consider cytokine storm syndromes and immunosuppression Human CD56bright NK Cells: An Update RNA-Seq Signatures Normalized by 626 mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types Coronavirus disease (COVID-19) Situation 629 Coronavirus 631 infections: Epidemiological, clinical and immunological features and hypotheses edgeR: a Bioconductor 634 package for differential expression analysis of digital gene expression data Spatial 637 reconstruction of single-cell gene expression data Influenza 640 A Virus Infection Induces Hyperresponsiveness in Human Lung Tissue-Resident and 641 Peripheral Blood NK Cells Severe 644 COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment Novel 646 mechanisms of immune modulation of natalizumab in multiple sclerosis patients SARS-CoV-2 entry 650 factors are highly expressed in nasal epithelial cells together with innate immune 651 genes Expanding roles for CD4(+) T 653 cells in immunity to viruses A molecular cell atlas of the human lung 656 from single cell RNA sequencing. bioRxiv ggplot2: Elegant Graphics for Data Analysis A single-cell atlas of 661 the peripheral immune response in patients with severe COVID-19 Single-cell landscape of immunological responses in 665 patients with COVID-19 Heightened Innate Immune Responses in the Respiratory 668 Tract of COVID-19 Patients Single-Cell Sequencing of Peripheral Mononuclear Cells 671 Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza conditions, days after illness onset, and sex. The color scale is based on row-scaled 697 Boxplots showing the percentages of each cell type in four disease 698 conditions (HD, asymptomatic, moderate, and severe) and stages. Moderate patient 699 samples were divided into three stages based on days after symptom onset Mann-Whitney U-test was used for analysis Identification and characterization of the subpopulation of T and 705 innate immune cells in COVID-19 patients. a, UMAP of T and NK cells by Seurat Each dot represents an individual 707 cell. A total of 7 T cell subtypes and 7 innate immune cell subtypes were identified 708 and color-coded. b, Dot plot of average expression and percentage of expressed 709 cells of selected canonical markers in each labeled cell subtype. c, Proportions of 710 subtypes in each sample in different disease conditions Dot plot showing the average expression and percentage of expressed cells of 713 selected differentially expressed genes (DEGs) between 3 NK subtypes and Th2-like 714 subset. e-f, Heatmap of selected DEGs between different condition for CD56 bri CD16 -715 (e) and CD56 bri CD16 + (f) NK cell subtypes. The color scale is based on row-scaled z-716 score of gene expression. g-h, Violin plots showing expression of selected DEGs CD4 + (g) and CD8 + (h) effector T cell subsets Bar plots 720 showing the numbers of TCR detected in each T and NK cell subtype. b, The 721 percentage of the clonal status of T cells with TCR. The clonal status was defined by 722 clone size in four disease conditions. c, UMAP of T cells derived from PBMCs for 723 moderate and asymptomatic patients. Clusters are denoted by colors labeled with 724 TCR clones with top5 largest clone size in moderate patients, and TCR clones with 725 top5 largest clone size are shown in asymptomatic patients. d, TCR abundance and 726 diversity across disease conditions and stages generated by alakazam package. The 727 95% confidence interval is estimated via bootstrapping (B = 200). e, Heatmaps of the 728 difference in TRA/B rearrangement in four conditions Each 732 dot represents a single cell, colored according to cell type. b, Dot plot of canonical 733 cell markers used to annotate clusters in the UMAP plot. c, Boxplots showing the 734 differences in percentages of each cell type comparing different disease conditions to 735 healthy control. Two-sided unpaired Mann-Whitney U-test was used for analysis, and 736 a p-value < 0.05 is considered significant. d, The percentage of clonal status in B 737 cells that have BCR, across disease conditions and stages. e, Boxplots showing the 738 proportion of IgG, IgM, IgD, and IgA comparing different disease conditions to healthy 739 control. Two-sided unpaired Mann-Whitney U-test was used for analysis DEGs generated by comparing different conditions